Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma
- The primary endpoint (antitumor effect) was achieved - No new safety concerns were identified in the…
- The primary endpoint (antitumor effect) was achieved - No new safety concerns were identified in the…
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will end the production of…
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited ACN 058 466 523 (Company) is pleased…
Tapped as BORN’s exclusive PIM partner, Akeneo’s Product Experience Management (PXM) capabilities well complement BORN’s…
HONG KONG--(BUSINESS WIRE)--Recently, FPS+Roguelite game Gunfire Reborn developed by Duoyi (Hong Kong) Interactive starts Early…
Devart rolled out the updated versions of dbExpress drivers with support for the newly released…
Data from a Phase II trial show a regimen of Truxima® (biosimilar rituximab), lenalidomide and…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd (ASX: BRN), a leading provider of Ultra-Low Power, high…
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited…
Mohali, India, June 14, 2020 --(PR.com)-- A simple gateway for billing at Kohli Media LLP.KohliPay…